These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20601292)

  • 1. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2010 Oct; 47(4):729-35. PubMed ID: 20601292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and risks of raloxifene by vertebral fracture status.
    Sontag A; Wan X; Krege JH
    Curr Med Res Opin; 2010 Jan; 26(1):71-6. PubMed ID: 19908937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y; Wong M; Thiebaud D; Stock JL
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S; Klemes AB; Zhou X; Lindsay R
    J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Muscle and bone health as a risk factor of fall among the elderly. Role of raloxifene in the prevention of osteoporotic fractures].
    Ohta H
    Clin Calcium; 2008 Jun; 18(6):828-35. PubMed ID: 18515954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
    Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
    Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
    Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Gentilella R; Agnusdei D; Iori N; Nuti R;
    J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
    Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.